Reactions Weekly

, Volume 1696, Issue 1, pp 5–5 | Cite as

Dipeptidyl peptidase-4 inhibitors increase risk of IBD

Clinical study


  1. Abrahami D, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018: k872, No. 360, 21 Mar 2018. Available from: URL: CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations